Literature DB >> 19595898

Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials".

Paul S Aisen1.   

Abstract

Entities:  

Year:  2006        PMID： 19595898     DOI： 10.1016/j.jalz.2006.08.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  5 in total

1.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  Optimum Design of Disease-modifying Trials on Alzheimer's Disease.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; Ling Chen; Yan Yan
Journal:  Stat Biopharm Res       Date:  2012-08-30       Impact factor: 1.452

3.  Optimizing parameters in clinical trials with a randomized start or withdrawal design.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; John C Morris
Journal:  Comput Stat Data Anal       Date:  2014-01-01       Impact factor: 1.681

4.  Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.

Authors:  Chengjie Xiong; Gerald van Belle; J Philip Miller; John C Morris
Journal:  Clin Trials       Date:  2011-02       Impact factor: 2.486

5.  Long-term course and effectiveness of combination therapy in Alzheimer disease.

Authors:  Alireza Atri; Lynn W Shaughnessy; Joseph J Locascio; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.